Related Experiment Video
Updated: May 5, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures
Beth H Shaz1, Joseph Schwartz, Jeffrey L Winters
1New York Blood Center, New York, New York; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
The decision to treat a patient with therapeutic apheresis depends on multiple factors, such as what does the patient most likely have, is the diagnosis amenable to apheresis treatment, what is the harm-versus-benefit ratio of apheresis treatment in this patient, and what are the internal and external issues associated with receiving apheresis treatment? The "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-based Approach from the Writing Committee of the American Society for Apheresis" addresses these issues and helps aid in clinical decision making. The development and application of these Guidelines as well as potential new applications will be discussed in this article.
The decision to treat a patient with therapeutic apheresis depends on multiple factors, such as what does the patient most likely have, is the diagnosis amenable to apheresis treatment, what is the harm-versus-benefit ratio of apheresis treatment in this patient, and what are the internal and external issues associated with receiving apheresis treatment? The "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-based Approach from the Writing Committee of the American Society for Apheresis" addresses these issues and helps aid in clinical decision making. The development and application of these Guidelines as well as potential new applications will be discussed in this article.
More Related Videos
05:31Isolation, Cryopreservation and Culture of Human Amnion Epithelial Cells for Clinical Applications
Published on: December 21, 2014
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021